Tag: Immunotherapy
OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30
At the annual congress of the Société Francophone de Transplantation Supported by the European Society of Organ Transplantation (ESOT) Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics…
MaaT Pharma announces poster presentation at the 38th annual conference of the Society for Immunotherapy of Cancer (SITC) – 09/27/2023 at 6:17 p.m.
Lyon, France, September 27, 2023 – 6:00 p.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical-stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM…
OSE Immunotherapeutics presents advances in its research programs at upcoming international conferences CICON International Conference (Cancer Immunotherapy Conference) SITC Congress (Society for Immunotherapy of Cancer) PEGS Europe (Protein & Antibody Engineering Summit) – 09/20/2023 at 07 :30
Nantes, France – September 20, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the scientific advances from its research programs have been selected for presentation…
After cancer surgery: Immunotherapy is pending for Daniel Aminati’s wife
After cancer surgery Immunotherapy is pending for Daniel Aminati’s wife For Patrice Aminati, the medical marathon is not over. © imago images/eventfoto54 Patrice Aminati received detailed test results after her…
Chemotherapy, immunotherapy… What if nanoparticles were added to treat cancer?
Yasmina Kattou 08:48, January 13, 2023 In Bordeaux, a team of researchers are betting on a new technology, nanoparticles, to treat patients with glioblastoma, one of the most dangerous brain…
Novel immunotherapy with CAR-T cells
AWhen Ricarda K. was 15 years old, the disease broke out. She developed butterfly erythema: a flat reddening of the facial skin that is typical of systemic lupus erythematosus (SLE),…
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 – 11/14/2022 at 08:00
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in…
Transgene and BioInvent win the Best Article award in the Oncolytic and Local Immunotherapy category awarded by the JITC, for their work on BT-001 – 2022-11-14 at 08:00
Article, Featured at SITC 2022, Demonstrates the Potential of Innovative Anti-CTLA-4 Antibody Delivery This award further highlights the potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent, currently…
SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 37TH ANNUAL MEETING: NANOBIOTIX PRESENTS UPDATED PHASE 1 DATA ON COMBINATION OF NBTXR3 WITH ANTI-PD-1, WHICH MAY SUPPORT RADIOENHANCER’S IMMUNE SYSTEM-BOOSTING POTENTIAL – 10 /11/2022 at 08:30
These data will be discussed during the conference call presenting Nanobiotix’s third quarter results, at 8 a.m. EST / 2 p.m. CET. • Data from the entire dose escalation part…
OSE Immunotherapeutics provides an update on Tedopi®, a therapeutic cancer vaccine, a potential new reference treatment in non-small cell lung cancer after failure of immunotherapy – 10/20/2022 at 6:00 p.m.
Nantes, France – October 20, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), provides an update on Tedopi®, an immunotherapy for the activation of specific T lymphocytes…
NANOBIOTIX ESTABLISHES RECOMMENDED DOSE FOR REGISTRATION STUDY EVALUATING NBTXR3 + ANTI-PD-1 COMBINATION IN PATIENTS WITH METASTATIC HEAD AND NECK CANCER AND IMMUNOTHERAPY RESISTANT – 09/21/2022 at 22 :20
• Recommended dose for phase 2 of the dose escalation part of study 1100, established at 33% of the tumor volume (GTV) in the three cohorts of the study. •…
Next setback for Bavencio: Merck study on cancer immunotherapy failed
Another setback for Bavencio Merck study on cancer immunotherapy failed 2/8/2022, 5:01 p.m Merck only had to cope with two study flops in connection with a cancer drug last year.…